Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616667 | 0.95 | TDP1 (0.49) | ALDH1A1GAAEPHX1SMN1; SMN2LMNA | |
| SCHEMBL26698336 | 0.86 | KMT2A (0.47) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL2616661 | 0.85 | ALDH1A1 (0.46) | ALDH1A1GAALMNAKDM4EHPGD | |
| SCHEMBL2616718 | 0.84 | TDP1 (0.49) | ALDH1A1GAAEPHX1SMN1; SMN2LMNA | |
| SCHEMBL612716 | 0.83 | SMN1; SMN2 (0.46) | ALDH1A1GAASMN1; SMN2LMNAKDM4E | |
| SCHEMBL2347336 | 0.83 | GAA (0.70) | ALDH1A1GAAEPHX1SMN1; SMN2LMNA | |
| SCHEMBL28862350 | 0.81 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2LMNAKDM4EHPGD | |
| SCHEMBL2616713 | 0.81 | TDP1 (0.55) | ALDH1A1GAAEPHX1SMN1; SMN2LMNA | |
| SCHEMBL29288458 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAKDM4ETSHR | |
| SCHEMBL9516216 | 0.80 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2LMNAKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511484-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | Promega Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119095959-A | Compounds, compositions and methods for isolating nucleic acids | 普罗美加公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION | 2023-11-30 | — | — | US | disclosed |
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION | 2023-11-30 | — | — | US | disclosed |
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION | 2023-11-30 | — | — | US | disclosed |
| WO-2023205450-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | PROMEGA CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382875-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDS | POLRMT, POLN, NOP2 | ALDH1A1 3155/4885GAA 1208/4885EPHX1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.